Comparing Moleculin Biotech (NASDAQ:MBRX) & Cingulate (NASDAQ:CING)

Moleculin Biotech (NASDAQ:MBRX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Volatility & Risk

Moleculin Biotech has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500.

Profitability

This table compares Moleculin Biotech and Cingulate’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-60.88%
Cingulate	N/A	-509.72%	-172.37%

Insider & Institutional Ownership

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 4.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Moleculin Biotech and Cingulate, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1	0	2	0	2.33
Cingulate	1	0	2	0	2.33

Moleculin Biotech currently has a consensus target price of $22.00, suggesting a potential upside of 825.93%. Cingulate has a consensus target price of $34.50, suggesting a potential upside of 571.86%. Given Moleculin Biotech’s higher possible upside, equities analysts plainly believe Moleculin Biotech is more favorable than Cingulate.

Valuation and Earnings

This table compares Moleculin Biotech and Cingulate”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56 million	($32.75)	-0.07
Cingulate	N/A	N/A	-$22.45 million	($4.32)	-1.19

Cingulate is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Moleculin Biotech beats Cingulate on 5 of the 9 factors compared between the two stocks.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

About Cingulate

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.